Answers are grounded in this paper and cite their sources.
Traumatic brain injury (TBI) remains a leading cause of long-term disability worldwide, yet disease-modifying therapies targeting chronic neuroinflammation remain scarce. Emerging evidence has positioned the gut microbiome as a critical modulator of post-TBI outcomes, with Akkermansia muciniphila emerging as a particularly promising candidate. Preclinical studies demonstrate that Akkermansia supplementation alleviates persistent microglial activation and improves cognitive function in TBI models. Mechanistically, multi-omics analyses reveal that Akkermansia effectively blocks TBI-induced elevation of sphingolipid metabolism, a pathway closely linked to sustained microglial reactivity. The bacterium modulates microglial function through both indirect pathways involving short-chain fatty acids and tryptophan metabolites, and direct interactions via outer membrane proteins and extracellular vesicles. This review synthesizes current evidence indicating that, in preclinical TBI models, A. muciniphila is a candidate neuroimmune modulator that may bridge gut dysbiosis to microglial dysfunction through sphingolipid metabolism, thereby offering a hypothesis-generating preclinical rationale for mitigating the chronic consequences of traumatic brain injury.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: